Physician profile
Hannah Patterson
NPI 1386107985
$4,074.98
in general payments reported to CMS, 2019-2025
29 companies · $29.50 in 2025
The $29.50 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $423 · 2023: $3,353 · 2024: $122 · 2025: $29.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284 · Travel and Lodging: $205 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.57 |
| Travel and Lodging | $205.00 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.37 | 2021-2025 | |
| Enterra Medical, INC. | $473.79 | 2023 | |
| Celgene Corporation | $348.33 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $327.35 | 2022-2023 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $316.27 | 2023-2024 | Ibsrela |
| Gilead Sciences, INC. | $254.77 | 2022-2023 | Vemlidy |
| Genzyme Corporation | $205.51 | 2023 | |
| Nestle Healthcare Nutrition INC. | $187.75 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $118.91 | 2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $107.16 | 2023 | Ocaliva |
| Nevro Corp. | $100.86 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $94.57 | 2022-2023 | Dupixent |
| Amgen INC. | $93.45 | 2023 | Amjevita, Avsola |
| Janssen Biotech, INC. | $89.91 | 2023 | Stelara |
| Depuy Synthes Sales INC. | $73.02 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $63.10 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $46.46 | 2023 | Entyvio, Gattex |
| Evoke Pharma, INC. | $36.71 | 2023 | Gimoti |
| Grt US Holding, INC. | $24.85 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.79 | 2022 | |
| Spr Therapeutics, INC | $20.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.31 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $19.47 | 2023 | Dificid, Recarbrio |
| Fresenius Kabi USA, LLC | $19.18 | 2023 | Idacio |
| Pfizer INC. | $18.33 | 2023 | |
| Integra Lifesciences Corporation | $16.13 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.57 | 2021 | |
| Vivus LLC | $12.93 | 2023 | Qsymia |
| Arteriocyte Medical Systems, INC. | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.